Characteristics of COPD Patients Initiating Treatment with Aclidinium or Tiotropium in Primary Care in Catalonia: a Population-based Study

Overview

Journal Int J Chron Obstruct Pulmon Dis

Publisher Dove Medical Press

Specialty Pulmonary Medicine

Date 2017 Apr 27

PMID 28442901

Citations 5

Authors

Monica Monteagudo

Montse Roset

Teresa Rodriguez-Blanco

Laura Munoz

Marc Miravitlles

Affiliations

Soon will be listed here.

Abstract

Objective: To describe and compare demographic and clinical profile of patients newly initiated on aclidinium (ACL) or tiotropium (TIO) and identify factors associated with newly initiated ACL in real-life clinical practice during 2013 in Catalonia.

Design: We performed a population-based, retrospective, observational study with data obtained from the Information System for Research Development in Primary Care, a population database that contains information of 5.8 million inhabitants (more than 80% of the Catalan population). Patients over 40 years old, with a recorded diagnosis of COPD and newly initiated treatment with either ACL or TIO during the study period (January to December 2013), were selected. A descriptive analysis of demographic and clinical characteristics was performed, and treatment adherence was also assessed for both cohorts.

Results: A total of 8,863 individuals were identified, 4,293 initiated with ACL and 4,570 with TIO. They had a mean age of 69.4 years (standard deviation: 11.3), a median COPD duration of 3 years (interquartile range: 0-8), and 71% were males. Patients treated with ACL were older, with more respiratory comorbidities, a longer time since COPD diagnosis, worse forced expiratory volume in 1 second (% predicted), and with a higher rate of exacerbations during the previous year compared with TIO. It was found that 41.3% of patients with ACL and 62.3% of patients with TIO had no previous COPD treatment. Inhaled corticosteroid and long-acting β2-agonist were the most frequent concomitant medications (32.9% and 32.6%, respectively). Approximately 75% of patients were persistent with ACL or TIO at 3 months from the beginning of treatment, and more than 50% of patients remained persistent at 9 months.

Conclusion: Patients initiated with ACL had more severe COPD and were taking more concomitant respiratory medications than patients initiated with TIO. ACL was more frequently initiated as part of triple therapy, while TIO was more frequently initiated as monotherapy.

Citing Articles

Methods to assess COPD medications adherence in healthcare databases: a systematic review.

Vauterin D, Van Vaerenbergh F, Vanoverschelde A, Quint J, Verhamme K, Lahousse L Eur Respir Rev. 2023; 32(169).

PMID: 37758274 PMC: 10523153. DOI: 10.1183/16000617.0103-2023.

Clinical characteristics and factors associated with triple therapy use in newly diagnosed patients with COPD.

Monteagudo M, Barrecheguren M, Solntseva I, Dhalwani N, Booth A, Nunez A NPJ Prim Care Respir Med. 2021; 31(1):16.

PMID: 33753747 PMC: 7985144. DOI: 10.1038/s41533-021-00227-x.

Cost-effectiveness analysis of umeclidinium bromide/vilanterol 62.5/25 mcg versus tiotropium/olodaterol 5/5 mcg in symptomatic patients with chronic obstructive pulmonary disease: a Spanish National Healthcare System perspective.

Driessen M, Whalen J, Buguth B, Vallejo-Aparicio L, Naya I, Asukai Y Respir Res. 2018; 19(1):224.

PMID: 30458866 PMC: 6245710. DOI: 10.1186/s12931-018-0916-7.

Population-based study of LAMA monotherapy effectiveness compared with LABA/LAMA as initial treatment for COPD in primary care.

Barrecheguren M, Monteagudo M, Miravitlles M NPJ Prim Care Respir Med. 2018; 28(1):36.

PMID: 30266978 PMC: 6162319. DOI: 10.1038/s41533-018-0102-x.

Respiratory medication used in COPD patients from seven Latin American countries: the LASSYC study.

Casas A, Montes de Oca M, Menezes A, Wehrmeister F, Lopez Varela M, Mendoza L Int J Chron Obstruct Pulmon Dis. 2018; 13:1545-1556.

PMID: 29785104 PMC: 5955011. DOI: 10.2147/COPD.S154097.

References

Blasi F, Raddi F, Miravitlles M . Interactive Monitoring Service and COPD: Is it Possible to Reduce Nonadherence?. COPD. 2014; 12(3):227-32. DOI: 10.3109/15412555.2014.933796. View

Miravitlles M, Anzueto A . A new two-step algorithm for the treatment of COPD. Eur Respir J. 2017; 49(2). DOI: 10.1183/13993003.02200-2016. View

Jones P, Singh D, Bateman E, Agusti A, Lamarca R, de Miquel G . Efficacy and safety of twice-daily aclidinium bromide in COPD patients: the ATTAIN study. Eur Respir J. 2012; 40(4):830-6. DOI: 10.1183/09031936.00225511. View

Luis Izquierdo J, Paredero J, Piedra R . Relevance of dosage in adherence to treatment with long-acting anticholinergics in patients with COPD. Int J Chron Obstruct Pulmon Dis. 2016; 11:289-93. PMC: 4755690. DOI: 10.2147/COPD.S96948. View

Jones P, Leidy N, Hareendran A, Lamarca R, Chuecos F, Garcia Gil E . The effect of aclidinium bromide on daily respiratory symptoms of COPD, measured using the Evaluating Respiratory Symptoms in COPD (E-RS: COPD) diary: pooled analysis of two 6-month Phase III studies. Respir Res. 2016; 17(1):61. PMC: 4877996. DOI: 10.1186/s12931-016-0372-1. View

Miravitlles M, Mayordomo C, Artes M, Nicolau F, Segu J . Treatment of chronic obstructive pulmonary disease and its exacerbations in general practice. EOLO Group. Estudio Observacional de la Limitación Obstructiva al Flujo aEreo. Respir Med. 1999; 93(3):173-9. DOI: 10.1016/s0954-6111(99)90004-5. View

Roche N, Reddel H, Martin R, Brusselle G, Papi A, Thomas M . Quality standards for real-world research. Focus on observational database studies of comparative effectiveness. Ann Am Thorac Soc. 2014; 11 Suppl 2:S99-104. DOI: 10.1513/AnnalsATS.201309-300RM. View

Brusselle G, Price D, Gruffydd-Jones K, Miravitlles M, Keininger D, Stewart R . The inevitable drift to triple therapy in COPD: an analysis of prescribing pathways in the UK. Int J Chron Obstruct Pulmon Dis. 2015; 10:2207-17. PMC: 4621207. DOI: 10.2147/COPD.S91694. View

Beier J, Kirsten A, Mroz R, Segarra R, Chuecos F, Caracta C . Efficacy and safety of aclidinium bromide compared with placebo and tiotropium in patients with moderate-to-severe chronic obstructive pulmonary disease: results from a 6-week, randomized, controlled Phase IIIb study. COPD. 2013; 10(4):511-22. PMC: 3787813. DOI: 10.3109/15412555.2013.814626. View

10.

Barrecheguren M, Monteagudo M, Ferrer J, Borrell E, Llor C, Esquinas C . Treatment patterns in COPD patients newly diagnosed in primary care. A population-based study. Respir Med. 2016; 111:47-53. DOI: 10.1016/j.rmed.2015.12.004. View

11.

Anzueto A, Miravitlles M . Efficacy of tiotropium in the prevention of exacerbations of COPD. Ther Adv Respir Dis. 2009; 3(3):103-11. DOI: 10.1177/1753465809338854. View

12.

Roche N, Jebrak G, Caillaud D, Deslee G, Brinchault G, Chanez P . Real-life use of long-acting antimuscarinic agents following their approval for COPD treatment. Eur Respir J. 2014; 45(1):260-2. DOI: 10.1183/09031936.00131614. View

13.

Cramer J, Bradley-Kennedy C, Scalera A . Treatment persistence and compliance with medications for chronic obstructive pulmonary disease. Can Respir J. 2007; 14(1):25-9. PMC: 2690446. DOI: 10.1155/2007/161652. View

14.

Monteagudo M, Rodriguez-Blanco T, Parcet J, Penalver N, Rubio C, Ferrer M . Variability in the performing of spirometry and its consequences in the treatment of COPD in primary care. Arch Bronconeumol. 2011; 47(5):226-33. DOI: 10.1016/j.arbres.2010.10.009. View

15.

Arfe A, Nicotra F, Cerveri I, de Marco R, Vaghi A, Merlino L . Incidence, Predictors, and Clinical Implications of Discontinuing Therapy with Inhaled Long-Acting Bronchodilators among Patients with Chronic Obstructive Pulmonary Disease. COPD. 2016; 13(5):540-6. DOI: 10.3109/15412555.2016.1141877. View

16.

Miravitlles M, Soler-Cataluna J, Calle M, Molina J, Almagro P, Quintano J . Spanish guideline for COPD (GesEPOC). Update 2014. Arch Bronconeumol. 2014; 50 Suppl 1:1-16. DOI: 10.1016/S0300-2896(14)70070-5. View

17.

Bolibar B, Fina Aviles F, Morros R, Garcia-Gil M, Hermosilla E, Ramos R . [SIDIAP database: electronic clinical records in primary care as a source of information for epidemiologic research]. Med Clin (Barc). 2012; 138(14):617-21. DOI: 10.1016/j.medcli.2012.01.020. View

18.

Huurne K, Kort S, van der Palen J, van Beurden W, Movig K, van der Valk P . Quality of life and adherence to inhaled corticosteroids and tiotropium in COPD are related. Int J Chron Obstruct Pulmon Dis. 2016; 11:1679-88. PMC: 4968688. DOI: 10.2147/COPD.S107303. View

19.

Soler-Cataluna J, Sauleda J, Valdes L, Marin P, Aguero R, Perez M . Prevalence and Perception of 24-Hour Symptom Patterns in Patients With Stable Chronic Obstructive Pulmonary Disease in Spain. Arch Bronconeumol. 2016; 52(6):308-15. DOI: 10.1016/j.arbres.2015.11.010. View

20.

Price D, Miravitlles M, Pavord I, Thomas M, Wedzicha J, Haughney J . First maintenance therapy for COPD in the UK between 2009 and 2012: a retrospective database analysis. NPJ Prim Care Respir Med. 2016; 26:16061. PMC: 5093405. DOI: 10.1038/npjpcrm.2016.61. View